GENE ONLINE|News &
Opinion
Blog

Alzheimer's Drug
Eisai and Biogen’s Alzheimer’s Med, Leqembi, Granted FDA Approval
2023-01-09
Though Alzheimer’s Treatment Fails Presenting Primary Endpoints, TauRx is Still Seeking Approval
2022-10-06
Biogen Concludes $900 Million Settlement Before Posting Positive Data From Alzheimer’s Trial
2022-09-28
Alleviating Depression and Dementia with Transcorneal Electrical Stimulation
2022-07-11
Eisai and Biogen’s New Alzheimer’s Drug to Receive FDA Decision by January
2022-07-06
Eisai to File Another Biogen-Partnered Alzheimer’s Drug After Confidence Hit
2022-05-10
Biogen Halts Aduhelm’s Second EU Marketing Application
2022-04-25
CMS’s New Ruling on Biogen’s Aduhelm Restriction Coverage
2022-04-13
Alliance Formed: SV Investment and Orange Grove Bio Jointly Source and Develop Novel Medications in the U.S. and Korea
2022-03-16
A New Study Reveals Viagra Could Decrease the Risk of Alzheimer’s Disease
2021-12-08
Roche Bets on Shape’s RNA Editing Tech in $3B Gene Therapy Collab
2021-08-25
China’s Simcere Gains Regional Rights for Two Alzheimer’s Drugs
2021-07-01
LATEST
From Sweet to Risky: The Alarming Findings on Sucralose’s Genotoxicity
2023-06-07
GHG Emissions as a ESG Metric
2023-06-07
NSTC Joins Forces with Taiwan Biomedical Start-ups to Rise to the World Stage, Showcasing Innovations at US BIO’s Demo Day
2023-06-07
Krystal Biotech’s First Topical Gene Therapy Approved by FDA
2023-06-06
The Emergence of General AI for Medicine: Medical Applications of ChatGPT
2023-06-06
Strengthening Genetic Screening Platform in APAC for Lung Cancer Precision Medicine: An Interview with Dr. Koichi Goto
2023-06-05
2023 International Healthcare Week: Showcasing Emerging Competencies of Hong Kong’s Biomedical Industry
2023-06-05
Scroll to Top